CochLear Revenue 2023-2024 | CHEOY
CochLear annual/quarterly revenue history and growth rate from 2023 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- CochLear revenue for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- CochLear revenue for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- CochLear annual revenue for 2024 was $1.466B, a 12.48% increase from 2023.
- CochLear annual revenue for 2023 was $1.303B, a 8.99% increase from 2022.
- CochLear annual revenue for 2022 was $1.196B, a 3.73% increase from 2021.
| CochLear Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $1,466 |
| 2023 | $1,303 |
| 2022 | $1,196 |
| 2021 | $1,153 |
| 2020 | $887 |
| 2019 | $1,020 |
| 2018 | $1,057 |
| 2017 | $945 |
| 2016 | $824 |
| CochLear Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-12-31 | |
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.143B | $1.488B |
| Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.013B | 25.51 |
| CVS Health (CVS) | United States | $78.381B | 9.74 |
| Elevance Health (ELV) | United States | $62.395B | 8.39 |
| Cencora (COR) | United States | $56.765B | 19.75 |
| DiDi Global (DIDIY) | China | $26.874B | 28.55 |
| Labcorp Holdings (LH) | United States | $20.399B | 16.55 |
| Natera (NTRA) | United States | $18.966B | 0.00 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.991B | 0.00 |
| Solventum (SOLV) | United States | $12.678B | 13.42 |
| ICON (ICLR) | Ireland | $11.592B | 10.78 |
| Revvity (RVTY) | United States | $10.993B | 18.92 |
| Viatris (VTRS) | United States | $10.422B | 3.58 |
| Avantor (AVTR) | United States | $9.056B | 13.16 |
| Medpace Holdings (MEDP) | United States | $8.964B | 23.81 |
| Sonic Healthcare (SKHHY) | Australia | $8.852B | 0.00 |
| HealthEquity (HQY) | United States | $8.449B | 37.01 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.680B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.587B | 14.87 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.918B | 28.96 |
| BrightSpring Health Services (BTSG) | United States | $3.506B | 32.17 |
| Sotera Health (SHC) | United States | $3.139B | 17.84 |
| Surgery Partners (SGRY) | United States | $2.861B | 37.20 |
| Concentras Parent (CON) | United States | $2.507B | 14.49 |
| Organon (OGN) | United States | $2.459B | 2.61 |
| Alignment Healthcare (ALHC) | United States | $2.455B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.222B | 85.57 |
| Progyny (PGNY) | United States | $1.886B | 41.51 |
| PACS (PACS) | United States | $1.823B | 0.00 |
| Premier (PINC) | United States | $1.725B | 13.09 |
| GoodRx Holdings (GDRX) | United States | $1.672B | 33.43 |
| Ardent Health (ARDT) | United States | $1.589B | 6.77 |
| Teladoc Health (TDOC) | United States | $1.412B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $1.277B | 438.00 |
| Establishment Labs Holdings (ESTA) | $1.202B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.080B | 8.22 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.878B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.759B | 7.10 |
| CareDx (CDNA) | United States | $0.663B | 10.36 |
| Nutex Health (NUTX) | United States | $0.632B | 9.57 |
| So-Young (SY) | China | $0.595B | 0.00 |
| SBC Medicals (SBC) | United States | $0.585B | 0.00 |
| Embecta (EMBC) | United States | $0.572B | 3.85 |
| InnovAge Holding (INNV) | United States | $0.531B | 0.00 |
| LifeMD (LFMD) | United States | $0.479B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.470B | 10.58 |
| Sonida Senior Living (SNDA) | United States | $0.466B | 0.00 |
| Omada Health (OMDA) | $0.453B | 0.00 | |
| COMPASS Pathways (CMPS) | United Kingdom | $0.402B | 0.00 |
| Enhabit (EHAB) | United States | $0.342B | 28.12 |
| Oncology Institute (TOI) | United States | $0.312B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.297B | 0.00 |
| Beauty Health (SKIN) | United States | $0.200B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.146B | 0.00 |
| DocGo (DCGO) | United States | $0.146B | 23.83 |
| Sera Prognostics (SERA) | United States | $0.110B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.079B | 0.00 |
| KindlyMD (NAKA) | United States | $0.066B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.060B | 0.00 |
| Biodesix (BDSX) | United States | $0.047B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.044B | 0.00 |
| ModivCare (MODV) | United States | $0.043B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.043B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.020B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.015B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |